# Digitally enhanced fracture liaison service in Austria—a feasibility analysis

**Authors:** Aaron Pfender, Martina Behanova, Judith Haschka, Johannes Holinka, Daniela Kritsch, Daniel Mattes, Julia Kaufmann, Jochen Zwerina, Roland Kocijan

PMC · DOI: 10.1007/s11657-026-01691-z · Archives of Osteoporosis · 2026-03-24

## TL;DR

A digitally enhanced fracture liaison service in Austria can help identify and treat patients with osteoporosis after fractures, but requires dedicated staff for effectiveness.

## Contribution

Demonstrates the feasibility of integrating a digital fracture liaison service into routine hospital care for osteoporosis management.

## Key findings

- 38.1% of eligible patients with osteoporotic fractures were included in the digital FLS.
- 73.0% of patients received calcium and vitamin D supplementation during hospitalization.
- Dedicated staff are crucial for translating digital solutions into effective fracture prevention.

## Abstract

Fragility fractures often signal untreated osteoporosis. This study shows that a digitally enhanced Fracture Liaison Service (FLS) can identify affected patients in routine hospital care and improve structured assessment and treatment. Dedicated staff remain essential to translate digital solutions into effective fracture prevention.

Although Fracture Liaison Services (FLS) are established internationally, structured programs remain scarce in Austria. This study aimed to assess the real-world feasibility of a digitally supported, International Osteoporosis Foundation (IOF)–certified FLS implemented in routine inpatient care.

We conducted a retrospective, monocentric cohort study at a tertiary care hospital in Vienna, Austria. Hospitalized patients aged ≥ 50 years with major osteoporotic fractures were included in a digital FLS module integrated into the hospital information system between April 2023 and March 2024. Feasibility parameters included patient capture rate, implementation of standardized diagnostics, and initiation or recommendation of osteoporosis therapy.

Overall, 141 patients were enrolled (78% women; mean age 75.8 ± 11.4 years). Vertebral (31.9%) and hip fractures (25.5%) were the most frequent fracture sites. A previous fragility fracture was documented in 46.1% of patients; 24.1% had a prior diagnosis of osteoporosis. In total, 38.1% of all eligible inpatients with osteoporotic fractures were included in the digital FLS. Calcium and vitamin D supplementation was initiated during hospitalization in 73.0% of patients. Specific antiosteoporotic medication was initiated during the inpatient stay in 15.6% and in the outpatient setting in 9.9% and 8.5% of patients, respectively. Treatment was recommended for post-discharge initiation in 56.0% of cases. The most commonly prescribed drugs were denosumab and zoledronic acid.

Implementation of a digitally integrated FLS in routine inpatient care is feasible and enables structured identification, assessment, and treatment recommendation for patients with fragility fractures. However, limited staffing resources and challenges in post-discharge therapy implementation highlight the need for dedicated personnel and improved cross-sectoral care pathways.

The online version contains supplementary material available at 10.1007/s11657-026-01691-z.

## Linked entities

- **Chemicals:** calcium (PubChem CID 5460341), zoledronic acid (PubChem CID 68740)
- **Diseases:** osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}
- **Diseases:** vitamin D deficiency (MESH:D014808), Trauma (MESH:D014947), CRF (MESH:C565541), obese (MESH:D009765), type 2 diabetes (MESH:D003924), AOM (MESH:D000069279), depression (MESH:D003866), MOF (MESH:D058866), uterine carcinoma (MESH:D014594), psychiatric (MESH:D001523), SD-CA (MESH:D012735), femoral neck fractures (MESH:D005265), rheumatoid arthritis (MESH:D001172), humerus (MESH:D006810), Fragility fractures (MESH:D005600), hip (MESH:D025981), thyroid disorders (MESH:D013959), metabolic skeletal disease (MESH:D008659), thyroid carcinoma (MESH:D013964), ALL (MESH:D054218), polytrauma (MESH:D009104), malignancy (MESH:D009369), hip fracture (MESH:D006620), overweight (MESH:D050177), sepsis (MESH:D018805), chronic pain (MESH:D059350), underweight (MESH:D013851), secondary hyperparathyroidism (MESH:D006962), RCC (MESH:D002292), Vertebral fractures (MESH:C535781), Osteoporosis (MESH:D010024), calcium metabolism disorders (MESH:D002128), FLS (MESH:D050723), radius fractures (MESH:D011885), pelvic fractures (MESH:D034161)
- **Chemicals:** 25-OH vitamin D (-), Calcium (MESH:D002118), 25-hydroxyvitamin D (MESH:C104450), alcohol (MESH:D000438), romosozumab (MESH:C557282), creatinine (MESH:D003404), phosphate (MESH:D010710), Teriparatide (MESH:D019379), Denosumab (MESH:D000069448), Magnesium (MESH:D008274), vitamin D (MESH:D014807), Zoledronic acid (MESH:D000077211)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013220/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013220/full.md

## References

4 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013220/full.md

---
Source: https://tomesphere.com/paper/PMC13013220